Thrombotic thrombocytopenic purpura
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Thrombotic thrombocytopenic purpura Classification and external resources | |
 | |
|---|---|
| Thrombotic Thrombocytopenic Purpura: Micro H&E low mag; myocardial cells: an excellent example of this condition. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology | |
| ICD-10 | M31.1 |
| ICD-9 | 446.6 |
| DiseasesDB | 13052 |
| MedlinePlus | 000552 |
| eMedicine | emerg/579 neuro/499 med/2265 |
| MeSH | D011697 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Thrombotic thrombocytopenic purpura (TTP or Moschcowitz disease) is a rare disorder of the blood-coagulation system, causing multiple blood clots to form in blood vessels around the body.[1] Most cases of TTP arise from deficiency or inhibition of the enzyme ADAMTS13, which is responsible for cleaving large multimers of von Willebrand factor.[1] This leads to hemolysis and end-organ damage, and may require plasmapheresis therapy.
Signs and symptoms
Classically, the following five symptoms are indicative of this elusive disease:
- Fluctuating neurological symptoms, such as bizarre behavior, altered mental status, stroke or headaches (65%);
- Kidney failure (46%);
- Fever (33%);
- Thrombocytopenia (low platelet count), leading to bruising or purpura;
- Microangiopathic hemolytic anemia (anemia, jaundice and a characteristic blood film).
A patient may notice dark urine from the hemolytic anemia. Because of the many small areas of ischemia produced by clots in the microvasculature, symptoms may be diffuse and fluctuating, including the classical bruising, confusion, or headache, but also nausea and vomiting (from ischemia in the GI tract or from central nervous system involvement), chest pain from cardiac ischemia, seizures, muscle and joint pain, etc.
Causes
TTP, as with other microangiopathic hemolytic anemias (MAHAs), is caused by spontaneous aggregation of platelets and activation of coagulation in the small blood vessels. Platelets are consumed in the coagulation process, and bind fibrin, the end product of the coagulation pathway. These platelet-fibrin complexes form microthrombi which circulate in the vasculature and cause shearing of red blood cells, resulting in hemolysis.
Roughly, there are two forms of TTP: idiopathic and secondary TTP. A special case is the inherited deficiency of ADAMTS13, known as the Upshaw-Schulman syndrome.
Idiopathic TTP
The idiopathic form of TTP was recently linked to the inhibition of the enzyme ADAMTS13 by antibodies, rendering TTP an autoimmune disease. ADAMTS13 is a metalloproteinase responsible for the breakdown of the so-called von Willebrand factor (vWF), a protein that links platelets, blood clots, and the blood vessel wall in the process of blood coagulation. Very large vWF molecules are more prone to lead to coagulation. Hence, without proper cleavage of vWF by ADAMTS13, coagulation occurs at a higher rate, especially in the part of the blood vessel system where vWF is most active due to high shear stress: in the microvasculature.
In idiopathic TTP, severely decreased (<5% of normal) ADAMTS13 activity can be detected in most (80%) patients, and inhibitors are often found in this subgroup (44-56%). The relationship of reduced ADAMTS13 to the pathogenesis of TTP is known as the Furlan-Tsai hypothesis, after the two independent researchers who published their research in the same issue of the New England Journal of Medicine in 1998.[1][1][1] This theory is seen as insufficient to explain the etiology of TTP, since many patients with hereditary lack of ADAMTS13 activity do not manifest clinical symptoms of TTP.
Secondary TTP
Secondary TTP is diagnosed when the patient's history mentions one of the known features associated with TTP. It comprises about 40% of all cases of TTP. Predisposing factors are:
- Cancer
- Bone marrow transplantation
- Pregnancy
- Medication use:
- Platelet aggregation inhibitors (ticlopidine and clopidogrel)
- Immunosuppressants (cyclosporine, mitomycin, tacrolimus/FK506, interferon-α)
- HIV-1 infection
The mechanism of secondary TTP is poorly understood, as ADAMTS13 activity is generally not as depressed as in idiopathic TTP, and inihibitors cannot be detected. Probable etiology may involve, at least in some cases, endothelial damage.
Upshaw-Schulman syndrome
A hereditary form of TTP is called the Upshaw-Schulman syndrome; this is generally due to inherited deficiency of ADAMTS13 (frameshift and point mutations). Patients with this inherited ADAMTS13 deficiency have a surprisingly mild phenotype, but develop TTP in clinical situations with increased von Willebrand factor levels, e.g. infection. Reportedly, 5-10% of all TTP cases are due to Upshaw-Schulman syndrome.
Treatment
Since the early 1990s, plasmapheresis has become the treatment of choice for TTP.[1] This is an exchange transfusion involving removal of the patient's blood plasma through apheresis and replacement with donor plasma (fresh frozen plasma or cryosupernatant); the procedure has to be repeated daily to eliminate the inhibitor and ablate the symptoms. Lactate dehydrogenase levels are generally used to monitor disease activity. Plasmapheresis may need to be continued for 1-8 weeks before patients with idiopathic TTP cease to consume platelets and begin to normalize their hemoglobin. No single laboratory test (platelet count, LDH, ADAMTS13 level, or inhibitory factor) is indicative of recovery; research protocols have used improvement or normalization of LDH as a measure for ending plasmapheresis. Although patients may be critically ill with failure of multiple organ systems during the acute illness, including renal failure, myocardial ischemia, and neurologic symptoms, recovery over several months may be complete in the absence of a frank myocardial infarct, stroke, or CNS hemorrhage.
Many TTP patients need additional immunosuppressive therapy, with glucocorticoid steroids (e.g. prednisolone or prednisone), vincristine, cyclophosphamide, splenectomy or a combination of the above. Rituximab, a monoclonal antibody targeting B cells, has been successfully used to treat patients with refractory disease.
Children with Upshaw-Schulman syndrome receive plasma every three weeks prophylactically; this maintains adequate levels of functioning ADAMTS13.
Epidemiology
The incidence of TTP is about 4-6 per million people per year. As with most other autoimmune disorders, idiopathic TTP occurs more often in women and blacks, while the secondary forms do not show this distribution.
Prognosis
The mortality rate is approximately 95% for untreated cases, but the prognosis is reasonably favorable (80-90%) for patients with idiopathic TTP diagnosed and treated early with plasmapheresis.
Approximately one-third of patients experiencing a TTP episode have a relapse within 10 years following their first attack.
Secondary TTP still has a dismal prognosis, with mortality rates despite treatment being reported as 59% to 100%.
History
TTP was initially described in a 16-year old girl by Dr Eli Moschcowitz of New York City in 1924.[1] Moschcowitz ascribed the disease (incorrectly) to a toxic cause. Moschcowitz noted that his 16 year-old patient had anemia; petechiae; microscopic hematuria; and at autopsy, disseminated microvascular thrombi. Since that time, the pathophysiology, etiology, and medical management of TTP has expanded.
See also
Notes
References
- Moake JL (2002). "Thrombotic microangiopathies". N. Engl. J. Med. 347 (8): 589–600. doi:10.1056/NEJMra020528. PMID 12192020.
External links
WikiDoc Research Resources for Thrombotic thrombocytopenic purpura | |
|---|---|
| Articles on Thrombotic thrombocytopenic purpura | Most recent articles on Thrombotic thrombocytopenic purpura • Most cited articles on Thrombotic thrombocytopenic purpura • Review articles on Thrombotic thrombocytopenic purpura • Articles on Thrombotic thrombocytopenic purpura in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Thrombotic thrombocytopenic purpura | Powerpoint slides on Thrombotic thrombocytopenic purpura • Images of Thrombotic thrombocytopenic purpura • Photos of Thrombotic thrombocytopenic purpura • Podcasts & MP3s on Thrombotic thrombocytopenic purpura • Videos on Thrombotic thrombocytopenic purpura |
| Evidence Based Medicine Regarding Thrombotic thrombocytopenic purpura | Cochrane Collaboration on Thrombotic thrombocytopenic purpura • Bandolier on Thrombotic thrombocytopenic purpura • TRIP on Thrombotic thrombocytopenic purpura |
| Cost Effectiveness of Thrombotic thrombocytopenic purpura | Cost Effectiveness of Thrombotic thrombocytopenic purpura |
| Clinical Trials Involving Thrombotic thrombocytopenic purpura | Ongoing Trials on Thrombotic thrombocytopenic purpura at Clinical Trials.gov • Trial results on Thrombotic thrombocytopenic purpura • Clinical Trials on Thrombotic thrombocytopenic purpura at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Thrombotic thrombocytopenic purpura | US National Guidelines Clearinghouse on Thrombotic thrombocytopenic purpura • NICE Guidance on Thrombotic thrombocytopenic purpura • NHS PRODIGY Guidance • FDA on Thrombotic thrombocytopenic purpura • CDC on Thrombotic thrombocytopenic purpura |
| Textbook Information on Thrombotic thrombocytopenic purpura | Books and Textbook Information on Thrombotic thrombocytopenic purpura |
| Pharmacology Resources on Thrombotic thrombocytopenic purpura | Dosing of Thrombotic thrombocytopenic purpura • Drug interactions with Thrombotic thrombocytopenic purpura • Side effects of Thrombotic thrombocytopenic purpura • Allergic reactions to Thrombotic thrombocytopenic purpura • Overdose information on Thrombotic thrombocytopenic purpura • Carcinogenicity information on Thrombotic thrombocytopenic purpura • Thrombotic thrombocytopenic purpura in pregnancy • Pharmacokinetics of Thrombotic thrombocytopenic purpura • |
| Genetics, Pharmacogenomics, and Proteinomics of Thrombotic thrombocytopenic purpura | Genetics of Thrombotic thrombocytopenic purpura • Pharmacogenomics of Thrombotic thrombocytopenic purpura • Proteomics of Thrombotic thrombocytopenic purpura |
| Newstories on Thrombotic thrombocytopenic purpura | Thrombotic thrombocytopenic purpura in the news • Be alerted to news on Thrombotic thrombocytopenic purpura • News trends on Thrombotic thrombocytopenic purpura |
| Commentary on Thrombotic thrombocytopenic purpura | Blogs on Thrombotic thrombocytopenic purpura |
| Patient Resources on Thrombotic thrombocytopenic purpura | Patient resources on Thrombotic thrombocytopenic purpura • Discussion groups on Thrombotic thrombocytopenic purpura • Patient Handouts on Thrombotic thrombocytopenic purpura • Directions to Hospitals Treating Thrombotic thrombocytopenic purpura • Risk calculators and risk factors for Thrombotic thrombocytopenic purpura |
| Healthcare Provider Resources on Thrombotic thrombocytopenic purpura | Symptoms of Thrombotic thrombocytopenic purpura • Causes & Risk Factors for Thrombotic thrombocytopenic purpura • Diagnostic studies for Thrombotic thrombocytopenic purpura • Treatment of Thrombotic thrombocytopenic purpura |
| Continuing Medical Education (CME) Programs on Thrombotic thrombocytopenic purpura | CME Programs on Thrombotic thrombocytopenic purpura |
| International Resources on Thrombotic thrombocytopenic purpura | Thrombotic thrombocytopenic purpura en Espanol • Thrombotic thrombocytopenic purpura en Francais |
| Business Resources on Thrombotic thrombocytopenic purpura | Thrombotic thrombocytopenic purpura in the Marketplace • Patents on Thrombotic thrombocytopenic purpura |
| Informatics Resources on Thrombotic thrombocytopenic purpura | List of terms related to Thrombotic thrombocytopenic purpura |
de:Thrombotisch-thrombozytopenische Purpurafr:Purpura thrombotique thrombocytopénique it:Porpora trombotica trombocitopenica nl:Thrombotische thrombocytopenische purpura ja:血栓性血小板減少性紫斑病
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
